Serum DNase1, sTNFR1 and sTNFR2 as Risk Factors for Lupus Nephritis in Systemic Lupus Erythematosus Patients

Ida Ayu Ratih Wulansari Manuaba, Ketut Suryana, I Made Bakta, I Made Sudarmaja

Abstract


BACKGROUND: Early detection and management of lupus nephritis (LN) in systemic lupus erythematosus (SLE) are essential to prevent irreversible kidney damage and improve patient outcomes; therefore, identifying reliable biomarkers to predict LN is paramount. However, there are still relatively few studies examining the potential biomarkers for LN in SLE patients. This study was conducted to investigate serum deoxyribonuclease I (DNase), soluble tumor necrosing factor 1 (sTNFR1) and soluble tumor necrosing factor 2 (sTNFR2) as a risk factor for LN in SLE patients.

METHODS: A case-control study involving SLE patients aged 20-60 years was conducted. Blood was withdrawn from each subject for the measurement of serum level of DNase1, sTNFR1, and sTNFR2 that was performed using enzyme-linked immunoassay (ELISA) methods. Data was then analyzed using Chi-Square test and logistic regression tests.

RESULTS: A total of 22 patients with LN and 22 without LN were included. The cut-off value for DNase1, sTNFR1, and sTNFR2 were 5.05 ng/mL, 6.52 ng/mL, and 7.02 ng/mL, respectively. The risk factors of LN in SLE patients were the low level of serum DNase1 (aOR=6.64; 95%CI: 1.25-35.29; p=0.026), low level of serum sTNFR1 (aOR=8.12; 95% CI: 1.56-42.10; p=0.013), and low level of serum sTNFR2 (aOR=5.57; 95%CI: 1.03-30.11; p=0.046).

CONCLUSION: Serum DNase1 lower than 5.05 ng/mL, sTNFR1 lower than 6.52 ng/mL, and sTNFR2 lower than 7.02 ng/mL were risk factors for lupus nephritis in SLE patients. Hence, serum DNase1, sTNFR1 and sTNFR2 could be used as risk factors predictors for LN in SLE patients.

KEYWORDS: DNase1, sTNFR1, sTNFR2, SLE, lupus nephritis


Full Text:

PDF

References


Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression. Lupus. 2020; 29(9): 1011-20, CrossRef.

Lanata CM, Nititham J, Taylor KE, Chung SA, Torgerson DG, Seldin MF, et al. Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients. PLoS One. 2018; 13(6): e0199003, CrossRef.

Elsisi GH, Hsieh SC, Chen DY. The economic burden of systemic lupus erythematosus in Taiwan. J Med Econ. 2024; 27(Suppl1): 56-66, CrossRef.

Hocaoǧlu M, Valenzuela-Almada MO, Dabit JY, Osei-Onomah SA, Chevet B, et al. Incidence, prevalence, and mortality of lupus nephritis: A population-based study over four decades using the lupus midwest network. Arthritis Rheumatol. 2023; 75(4): 567-73, CrossRef.

Kenny EF, Raupach B, Abu Abed U, Brinkmann V, Zychlinsky A. Dnase1-deficient mice spontaneously develop a systemic lupus erythematosus-like disease. Eur J Immunol. 2019; 49(4): 590-9, CrossRef.

Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M. DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus. 2009; 18(5): 418-23, CrossRef.

Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M. DNase1 activity in systemic lupus erythematosus patients with and without nephropathy. Rheumatol Int. 2010; 30(12): 1601-4, CrossRef.

Skiljevic D, Jeremic I, Nikolic M, Andrejevic S, Sefik-Bukilica M, Stojimirovic B, et al. Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement. Clin Chem Lab Med. 2013; 51(5): 1083-91, CrossRef.

Richter P, Macovei LA, Mihai IR, Cardoneanu A, Burlui MA, Rezus E. Cytokines in systemic lupus erythematosus-focus on TNF-α and IL-17. Int J Mol Sci. 2023; 24(19): 14413, CrossRef.

Ghorbaninezhad F, Leone P, Alemohammad H, Najafzadeh B, Nourbakhsh NS, Prete M, et al. Tumor necrosis factor‑α in systemic lupus erythematosus: Structure, function and therapeutic implications (Review). Int J Mol Med. 2022; 49(4): 43, CrossRef.

Suntoko B, Hadisaputro S, Kalim H, Hadi S, Warlisti IV. A double-blind, randomized controlled trial of hydroxychloroquine for cognitive dysfunction and inflammatory biomarkers in systemic lupus erythematosus patients in Indonesia. Indones Biomed J. 2023; 15(4): 354-61, CrossRef.

Adhya Z, El Anbari M, Anwar S, Mortimer A, Marr N, Karim MY. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis. Lupus. 2019; 28(6): 713-21, CrossRef.

Patel M, Oni L, Midgley A, Smith E, Tullus K, Marks SD, et al. Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis. Lupus. 2016; 25(9): 1040-4, CrossRef.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725, CrossRef.

Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: Strengths, weaknesses, and opportunities for improvement. Lupus. 1999; 8(8): 586-95, CrossRef.

Camicia G, Muñoz SA, Allievi A, Orden AO, Perés Wingeyer S, et al. Association between severe disease course and nephritis with Q222R polymorphism in DNAse I gene among lupus patients: An Argentine multicenter study. Acta Reumatol Port. 2016; 41(2): 138-44, PMID.

Felux J, Erbacher A, Breckler M, Hervé R, Lemeiter D, Mannherz HG, et al. Deoxyribonuclease 1-mediated clearance of circulating chromatin prevents from immune cell activation and pro-inflammatory cytokine production, a phenomenon amplified by low trap1 activity: Consequences for systemic lupus erythematosus. Front Immunol. 2021; 12: 613597, CrossRef.

Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010; 107(21): 9813-8, CrossRef.

Engavale M, McCord J, Mapp B, Nzimulinda N, Bengtson E, Sutton RB, et al. Dnase1 Family in Autoimmunity. Encyclopedia. 2021; 1(3): 527-41, CrossRef.

Zykova SN, Tveita AA, Rekvig OP. Renal Dnase1 enzyme activity and protein expression is selectively shut down in murine and human membranoproliferative lupus nephritis. PLoS One. 2010; 5(8): e12096, CrossRef.

Liu XR, Qi YY, Zhao YF, Cui Y, Zhao ZZ. Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients. Ren Fail. 2023; 45(1): 2174355, CrossRef.

Zheng CZ, Yan WW, Luo YL, Wang TL, Shu YB. Value of sTNF-R1 and linc0597 as indicators for disease activity and diagnosis of lupus nephritis. Eur Rev Med Pharmacol Sci. 2020; 24(10): 5582-91, CrossRef.

Kartika R, Wibowo H. Impaired function of regulatory T cells in type 2 diabetes mellitus. Mol Cell Biomed Sci. 2020; 4(1): 1-9, CrossRef.

Parodis I, Ding H, Zickert A, Arnaud L, Larsson A, Svenungsson E, et al. Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. Scand J Rheumatol. 2017; 46(4): 263-72, CrossRef.

Mahmoud RAK, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem. 2005; 38(2): 134-41, CrossRef.

Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest. 2005; 115(5): 1199-209, CrossRef.

Lousa I, Reis F, Santos-Silva A, Belo L. The signaling pathway of TNF receptors: Linking animal models of renal disease to human CKD. Int J Mol Sci. 2022; 23(6): 3284, CrossRef.

Chung CH, Fan J, Lee EY, Kang JS, Lee SJ, Pyagay PE, et al. Effects of tumor necrosis factor-α on podocyte expression of monocyte chemoattractant protein-1 and in diabetic nephropathy. Nephron Extra. 2015; 5(1): 1-18, CrossRef.

Marks SD, Williams SJ, Tullus K, Sebire NJ. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant. 2008; 23(11): 3521-6, CrossRef.

Xia YR, Li QR, Wang JP, Guo HS, Bao YQ, Mao YM, et al. Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis. Lupus. 2020; 29(6): 599-606, CrossRef.

Surjawan Y, Intansari US. Suggested rational considerations for ANA-IF and ENA-profile test requisition: Clinical manifestation, gender, pattern, and riter of ANA-IF. Indones Biomed J. 2023; 15(3): 253-61, CrossRef.




DOI: https://doi.org/10.18585/inabj.v16i3.3052

Copyright (c) 2024 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Indexed by:

                  

               

                   

 

 

The Prodia Education and Research Institute